Testing effectiveness (Phase 2)Study completedNCT02162446What this trial is testing68Ga-OPS202 Study for Diagnostic Imaging of GEP NETWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Ipsen 12
Testing effectiveness (Phase 2)Study completedNCT03043664What this trial is testingStudy of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Duke University 22
Early research (Phase 1)Active Not RecruitingNCT04609592What this trial is testingStudy of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive SurgeryWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Stanford University 10
Large-scale testing (Phase 3)Active Not RecruitingNCT05459844What this trial is testingA Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsWho this might be right forNeuroendocrine Tumors Sinotau Pharmaceutical Group 196
Not applicableStudy completedNCT03017690What this trial is testingLanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)Who this might be right forGastroenteropancreatic Neuroendocrine Tumor Ipsen 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784What this trial is testingAbemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine TumorsWho this might be right forAdvanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more University of Washington 20
Not applicableLooking for participantsNCT07635316What this trial is testingTreatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Novartis Pharmaceuticals 4,023
Large-scale testing (Phase 3)Looking for participantsNCT05884255What this trial is testingAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Who this might be right forAdvanced Gastroenteropancreatic Neuroendocrine Tumor Jiangsu HengRui Medicine Co., Ltd. 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135What this trial is testingStudy to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsWho this might be right forGastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma Advanced Accelerator Applications 11
Testing effectiveness (Phase 2)Ended earlyNCT02078843What this trial is testingDiagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Insel Gruppe AG, University Hospital Bern 54
Not applicableStudy completedNCT05255133What this trial is testingEvaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA TreatmentWho this might be right forNeuroendocrine Tumors Universiteit Antwerpen 22
Testing effectiveness (Phase 2)Ended earlyNCT03042780What this trial is testingFOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasWho this might be right forGastro-enteropancreatic Neuroendocrine TumorPancreatic CancerNeuroendocrine Carcinomas of Pancreas+1 more H. Lee Moffitt Cancer Center and Research Institute 2
Testing effectiveness (Phase 2)Study completedNCT03079440What this trial is testingTEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more Asan Medical Center 31
Testing effectiveness (Phase 2)UnknownNCT03475953What this trial is testingA Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsWho this might be right forColorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more Institut Bergonié 747
Testing effectiveness (Phase 2)Study completedNCT02575300What this trial is testingPhase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsWho this might be right forCarcinoid TumorsPancreatic NET H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861What this trial is testingNal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETWho this might be right forGEP-NET National Health Research Institutes, Taiwan 52
Not applicableLooking for participantsNCT07302100What this trial is testingNutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University HospitalWho this might be right forGastroenteropancreatic Neuroendocrine Tumor University Hospital, Strasbourg, France 100
Large-scale testing (Phase 3)Looking for participantsNCT07185672What this trial is testingPRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)Who this might be right forNeuroendocrine Neoplasia's (NENs)Neuroendocrine Tumor GEP Grade 1-3Neuroendocrine Gastroenteropancreatic Tumour Tata Memorial Hospital 162
Not applicableStudy completedNCT04649580What this trial is testingUnited Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration SettingWho this might be right forNeuroendocrine Tumours (NET) Ipsen 80
Post-approval studies (Phase 4)Looking for participantsNCT05701241What this trial is testingContinuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtientsWho this might be right forGastroenteropancreatic Neuroendocrine Tumor University Hospital, Antwerp 270